查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年神經系統生物標誌物的全球市場
市場調查報告書
商品編碼
1270965

2023-2030 年神經系統生物標誌物的全球市場

Global Neurological Biomarker Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

神經生物標誌物的全球市場規模、份額和趨勢分析報告，按生物標誌物類型（成像生物標誌物、代謝組學生物標誌物、蛋白質組學生物標誌物、基因組學生物標誌物）、應用（阿爾茨海默病、帕金森病、多發病）、硬化症、自閉症譜系障礙等), 按最終用戶（醫院、臨床診斷中心、研究機構）預測期（2023-2030）

在預測期內，全球神經生物標誌物市場預計將以 12.4% 的複合年增長率顯著增長。 運動神經元病 (MND)、帕金森病 (PD)、中風、阿爾茨海默病 (AD)、亨廷頓舞蹈病 (HD) 等神經系統疾病以及腫瘤學、神經科學和心血管疾病 (CVD) 的患病率增加滿足全球經濟未滿足需求的生物樣本庫將加速市場增長。 根據加拿大組織儲存庫網絡 (CTRNet) 的數據，截至 2021 年 2 月，北美地區共有 278 個生物樣本庫。 此外，根據英國臨床研究社區組織名錄 (UKCRC-TD)，截至 2021 年 2 月，根據新南威爾士州健康病理學 (NSW-HP) 和英國的 274 家生物樣本庫，有 74 家生物樣本庫在增加。

此外，Fujirebio Diagnostics, Inc.、Thermo Fisher Scientific Inc. 和 Quanterix 等公司傾向於採用合作夥伴關係、協作和新產品發布等各種策略來推動市場增長，進一步推動市場增長。 例如，2023 年 3 月，Fujirebio Diagnostics, Inc. 和 AriBio Co, Ltd. 宣佈建立戰略合作夥伴關係，以推進阿爾茨海默病和其他神經退行性疾□□病生物標誌物的開發。 根據該協議，Fujirebio 將提供作為阿爾茨海默氏病 3 期試驗的一部分收集的臨床樣本和數據。

細分市場展望

全球神經生物標誌物市場根據生物標誌物類型、應用和最終用戶進行細分。 根據生物標誌物類型，市場分為成像生物標誌物、代謝組生物標誌物、蛋白質組生物標誌物和基因組生物標誌物。 根據應用，市場分為阿爾茨海默病、帕金森病、多發性硬化症、自閉症譜系障礙等。 基於最終用戶，市場分為醫院、臨床診斷中心和研究機構。 在最終用戶中，研究機構的子部分預計在未來幾年將出現顯著增長。 越來越多的研究人員參與識別血清和血漿中的關鍵生物標誌物，以及政府增加對研發中心的支出，預計將推動這一領域的增長。

預計帕金森病將佔據全球神經生物標誌物市場的很大份額。

按生物標誌物類型劃分，帕金森氏病子領域預計將在全球神經生物標誌物市場佔據很大份額。 這是由於越來越多的帕金森病藥物獲得批准，以及公眾對神經系統疾病的認識不斷提高，這推動了這一領域的增長。 例如，2023 年 1 月，Neuroderm 公佈了液體左旋多巴/卡比多巴 ND0612 的 III 期試驗結果。 左旋多巴暫時替代大腦化學物質多巴胺，並以較低的每日劑量在較長時間內控制帕金森病的運動症狀（震顫、緩慢和僵硬）。 它目前有片劑（口服）、吸入劑和凝膠（注射到小腸）的形式。 這種治療適用於患有帕金森氏病且無法通過口服藥物獲得最佳症狀控制的人。

區域展望

全球神經生物標誌物市場分為北美（美國、加拿大）、歐洲（英國、意大利、西班牙、德國、法國、歐洲其他地區）和亞太地區（印度、中國、日本、韓國、亞洲其他地區），以及世界其他地區（中東和非洲），按地區進一步細分。 北美地區預計將出現顯著的市場增長。 客戶越來越意識到使用生物標誌物診斷神經系統疾病、技術先進產品的可用性以及醫療保健基礎設施的改善是推動該地區市場增長的一些關鍵因素。已成為一個部門。

北美主導著全球神經生物標誌物市場

北美預計將在神經生物標誌物市場佔據顯著的市場份額。 這種高增長歸因於神經系統疾病患病率的上升和臨床試驗數量的增加。 例如，根據阿爾茨海默氏症協會的數據，到 2023 年，將有近 670 萬 65 歲及以上的美國人患有阿爾茨海默氏病，其中 73% 的年齡在 75 歲及以上。 在 65 歲以上的老人中，大約每 9 人中就有 1 人患有阿爾茨海默病，據說患有阿爾茨海默病的美國人中約有三分之二是女性。 FDA 對神經疾病的批准不斷增加也是推動市場增長的因素之一。 例如，2022年12月，美國FDA批准了霍夫曼羅氏公司開發的兩款新藥Elecsys Phospho-Tau (181P) CSF (pTau181)和Elecsys beta-Amyloid (1-42) CSF II (Abeta42) . 我們有兩種免疫測定在美國獲得批准。 這兩種測定法測量成年患者的兩種重要生物標誌物，tau 蛋白和 β-澱粉樣蛋白，以確認阿爾茨海默氏病的診斷。

市場參與者展望

全球神經生物標誌物市場的主要參與者包括 Abbott Laboratories、Bio-Rad Laboratories Inc.、Qiagen N.V.、Quanterix 和 Thermo Fisher Inc。 市場參與者通過採用併購、地域擴張、合作夥伴關係、產品發布和競爭等各種戰略來保持市場競爭力，為市場增長做出了重大貢獻。 例如，2020 年 9 月，美國國立衛生研究院 (NIH) 向北德克薩斯大學健康科學中心授予 4550 萬美元的研究經費，用於開發更多的生物標誌物。 這筆資金將用於了解墨西哥裔美國人和非拉丁裔白種人大腦老化的病理學。

本報告涵蓋：

  • 2022 年市場價值數據分析和到 2030 年的預測
  • 每個細分市場的年度市場銷售額
  • 主要地區的國家分析
  • 在全球神經生物標誌物市場運營的領先企業。 根據數據可用性，與新產品發布和相關新聞相關的信息也將包含在報告中。
  • 通過確定未來強勁增長的關鍵細分市場來分析業務戰略
  • 市場進入和市場擴張戰略分析
  • 通過識別市場中的“誰站在哪裡”來製定競爭策略

內容

第 1 章報告概述

  • 分析行業現狀和發展前景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師觀點和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第三章競爭格局

  • 主要公司分析
  • 雅培實驗室
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期趨勢
  • Bio-Rad 實驗室公司
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期發展狀況
  • Qiagen N.V.
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期發展狀況
  • Quanterix 公司
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期發展狀況
  • Thermo Fisher Scientific Inc.
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期發展狀況
  • 關鍵策略分析

第四章市場細分

  • 全球神經系統生物標誌物市場：按生物標誌物類型分類
    • 成像生物標誌物
    • 代謝組學生物標誌物
    • 蛋白質組學生物標誌物
    • 基因組學生物標誌物
  • 按應用劃分的全球神經系統生物標誌物市場
    • 阿爾茨海默氏癡呆症
    • 帕金森病 多發性硬化症）
    • 自閉症譜系
    • 其他（中風、癲癇等）
  • 全球神經系統生物標誌物市場：按最終用戶分類
    • 醫院
    • 臨床診斷中心
    • 研究所

按地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 世界其他地區

第二章公司簡介

  • Advanced Brain Monitoring, Inc.
  • AnaSpec
  • Athena Diagnostics, Inc.
  • BioMerieux, Inc.
  • C2N's Diagnostics
  • Enzo Life Sciences, Inc.,
  • Fujirebio Europe N.V
  • Imagilys
  • Labcorp
  • NanoSomiX, Inc
  • Neurosteer Ltd.
  • Proteome Sciences PLC
  • Psynova Neurotech Ltd.
  • Roche Diagnostics
Product Code: OMR2027234

Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), and by End Users (Hospital, Clinical Diagnostic Centers, Research Organizations) Forecast Period (2023-2030)

The global neurological biomarkers market is anticipated to grow at a significant CAGR of 12.4% during the forecast period. The increase in the prevalence of neurological diseases such as motor neuron disease (MND), Parkinson's disease (PD), stroke, Alzheimer's disease (AD), and Huntington's disease (HD), and the increase in biobanks for addressing unmet requirements in oncology, neuroscience, and cardiovascular disease (CVDs) to accelerate the market growth. According to the Canadian Tissue Repository Network (CTRNet), there are 278 biobanks in the North American region as of February 2021. Furthermore, according to the New South Wales Health Pathology (NSW-HP), there are 74 biobanks, and there are 274 biobanks in the UK as of February 2021, according to the UKCRC-TD, the UK Clinical Research Collaboration Tissue Directory.

In addition, companies including Fujirebio Diagnostics, Inc., Thermo Fisher Scientific Inc., Quanterix, and others are inclined towards adopting various strategies such as partnership, collaboration, and new product launches, that further drive market growth. For instance, in March 2023, Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer's disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the Phase 3 Alzheimer's disease study.

Segmental Outlook: 

The global neurological biomarkers market is segmented based on biomarker type, application, and end user. Based on biomarker type, the market is sub-segmented into imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Based on the application, the market is sub-segmented into Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Autism Spectrum Disorders, and others. Based on end user, the market is categorized into hospitals, clinical diagnostic centers, research organization. Among the end users, the research organization sub-segment is anticipated to grow at a significant rate in the coming years. An increasing number of researchers are involved in identifying key biomarkers in serum and plasma, and rising government expenditure for R&D centers to drive the segment growth.

The Parkinson's Disease Sub-Segment is Anticipated to Hold a Considerable Share of the Global Neurological Biomarkers Market

Among the biomarker type, the Parkinson's disease sub-segment to holds a prominent share of the global neurological biomarkers market. The growth is mainly attributed owing to the rising number of drug approval for the treatment of Parkinson's disease, coupled with increasing awareness among the people regarding the neurological diseases, drive the segment's growth. For instance, in January 2023, Neuroderm announced results from its Phase III trial on ND0612, a liquid levodopa/carbidopa. Levodopa temporarily replaces the dopamine brain chemical, and control Parkinson's motor symptoms (tremor, slowness, stiffness) for longer periods of time and with fewer doses each day. It's currently available as a pill (to take by mouth), inhaler or gel (for infusion into the small intestine). This treatment is for those people who are suffered form Parkinson's and are unable to achieve optimal symptom control with oral medications.

Regional Outlooks:

The global neurological biomarkers market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. The North American region is anticipated to witness considerable growth in the market. The rise in customer awareness about the use of biomarkers in diagnosing neurological disorders, the availability of technologically advanced products, and improved healthcare infrastructure, are some of the major factors that drive the market growth in the region.

The North America Region to Hold a Prominent Share of the Global Neurological Biomarkers Market

The North American region is projected to hold a prominent market share in the neurological biomarker market. This high growth is attributed to the rising prevalence of neurological diseases and the increasing number of clinical trials. For instance, according to the Alzheimer Association, nearly 6.7 million Americans age 65 and older are living with Alzheimer's in 2023, and 73% are aged 75 years and above. About 1 in 9 people aged 65 and older has Alzheimer's, and almost two-thirds of Americans with Alzheimer's are women. In addition, rising FDA approval for neurological disorder diseases is another factor that boosts market growth. For instance, in December 2022, the US FDA approved two immunoassays, Elecsys Phospho-Tau (181P) CSF (pTau181) and Elecsys beta-Amyloid (1-42) CSF II (Abeta42), developed by F. Hoffmann-La Roche Ltd. in the US. These two assays measure two important biomarkers-tau proteins and beta-amyloid-in adult patients to confirm the diagnosis of Alzheimer's disease.

Market Players Outlook:

The major companies serving the global neurological biomarkers market include Abbott Laboratories, Bio-Rad Laboratories Inc., Qiagen N.V., Quanterix, Thermo Fisher Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, geographical expansions, partnerships, product launches, and collaborations, to stay competitive in the market. For instance, in September 2020, the National Institutes of Health (NIH) granted research funding of $45.5 million to the University of North Texas Health Science Center for developing additional biomarkers. This funding is used for understanding the pathology of brain aging in Mexican Americans and non-Latino Whites populations.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global neurological biomarkers market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1.Research Methods and Tools
  • 1.2.Market Breakdown
    • 1.2.1.By Segments
    • 1.2.2.ByRegion

2.Market Overview and Insights

  • 2.1.Scope of the Report
  • 2.2.Analyst Insight and Current Market Trends
    • 2.2.1.Key Findings
    • 2.2.2.Recommendations
    • 2.2.3.Conclusion

3.Competitive Landscape

  • 1.1.Key Company Analysis
  • 3.1. Abbott Laboratories
    • 3.1.1.Overview
    • 3.1.2.Financial Analysis
    • 3.1.3.SWOT Analysis
    • 3.1.4.Recent Developments
  • 3.2.Bio-Rad Laboratories Inc. 
    • 3.2.1.Overview
    • 3.2.2.Financial Analysis
    • 3.2.3.SWOT Analysis
    • 3.2.4.Recent Developments
  • 3.3.Qiagen N.V.
    • 3.3.1.Overview
    • 3.3.2.Financial Analysis
    • 3.3.3.SWOT Analysis
    • 3.3.4.Recent Developments
  • 3.4.Quanterix Corp. 
    • 3.4.1.Overview
    • 3.4.2.Financial Analysis
    • 3.4.3.SWOT Analysis
    • 3.4.4.Recent Developments
  • 3.5.Thermo Fisher Scientific Inc.
    • 3.5.1.Overview
    • 3.5.2.Financial Analysis
    • 3.5.3.SWOT Analysis
    • 3.5.4.Recent Developments
  • 3.6.Key Strategy Analysis

4.Market Segmentation

  • 4.1.Global Neurological Biomarkers Market by Biomarker Type
    • 4.1.1.Imaging Biomarkers
    • 4.1.2.Metabolomics Biomarkers
    • 4.1.3.Proteomic Biomarkers
    • 4.1.4.Genomics Biomarkers
  • 4.2.Global Neurological Biomarkers Market by Application
    • 4.2.1.Alzheimer's Disease
    • 4.2.2.Parkinson's Disease
    • 4.2.3.Multiple Sclerosis
    • 4.2.4.Autism Spectrum Disorders
    • 4.2.5.Others (stroke, or epilepsy)
  • 4.3.Global Neurological Biomarkers Market by End User
    • 4.3.1.Hospital
    • 4.3.2.Clinical Diagnostic Centers
    • 4.3.3.Research Organizations

Regional Analysis

  • 1.2.North America
    • 1.2.1.US
    • 1.2.2.Canada
  • 1.3.Europe
    • 1.3.1.UK
    • 1.3.2.Germany
    • 1.3.3.Italy
    • 1.3.4.Spain
    • 1.3.5.France
    • 1.3.6.Rest of Europe
  • 1.4.Asia-Pacific
    • 1.4.1.China
    • 1.4.2.India
    • 1.4.3.Japan
    • 1.4.4.South Korea
    • 1.4.5.Rest of Asia-Pacific
  • 1.5.Rest of the World

2.Company Profiles

  • 2.1.Advanced Brain Monitoring, Inc. 
  • 2.2.AnaSpec 
  • 2.3.Athena Diagnostics, Inc.
  • 2.4.BioMerieux, Inc.
  • 2.5.C2N's Diagnostics
  • 2.6.Enzo Life Sciences, Inc.,
  • 2.7.Fujirebio Europe N.V
  • 2.8.Imagilys
  • 2.9.Labcorp 
  • 2.10.NanoSomiX, Inc
  • 2.11.Neurosteer Ltd.
  • 2.12.Proteome Sciences PLC
  • 2.13.Psynova Neurotech Ltd.
  • 2.14.Roche Diagnostics

LIST OF TABLES

  • 1.GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 2.GLOBAL IMAGING BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3.GLOBAL METABOLOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4.GLOBAL PROTEOMIC BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5.GLOBAL GENOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6.GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7.GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8.GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9.GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10.GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11.GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHER (STROKE, OR EPILEPSY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

  • 13.GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14.GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15.GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

  • 17.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 19.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 20.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 22.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 23.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 24.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 27.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 30.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 31.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 32.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY BIOLOGICAL TYPE, 2022 VS 2030 (%)
  • 2.GLOBAL IMAGING BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3.GLOBAL METABOLOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4.GLOBAL PROTEOMIC BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5.GLOBAL GENOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 7.GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER'S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8.GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON'S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9.GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10.GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11.GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHERS (STROKE OR EPILEPSY) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 13.GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14.GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15.GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET SHARE BY REGION, 2022 VS 2030 (%)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)

  • 17.US NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18.CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19.UK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20.FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21.GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22.ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23.SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25.INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26.CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27.JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28.SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)

REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)